Brandon A Kobayashi, MD
Medical Oncology · Ewa Beach
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 6
Offices
6 locations · The Queens Medical Center · Queens University Medical Group
Hospitals listed: The Queens Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Kobayashi’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A164599 · Delinquent
Licence status: Delinquent · since 2019 · expires 2025-08-31 · John A. Burns School of Medicine University of Hawaii at Manoa.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- The Queens Medical CenterHonolulu, HIAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of The Queens Health Systems, which runs 4 hospitalsPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.34 (1.12 to 1.55), Jul 2022 – Jun 2024Worse than the national rate — Iatrogenic pneumothorax rate: 0.47 (0.29 to 0.65) · 11,638 cases, Jul 2022 – Jun 2024Worse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.32 (3.74 to 6.9) · 3,569 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.79 (1.36 to 2.23) · 10,444 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.453, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.427, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.345, Oct 2024 – Sep 2025
See every measure and the patient survey for The Queens Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 3 better, 3 the same, 2 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.34 (1.12 to 1.55) | Worse | Jul 2022 – Jun 2024 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.47 (0.29 to 0.65) · 11,638 cases | Worse | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.32 (3.74 to 6.9) · 3,569 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.79 (1.36 to 2.23) · 10,444 cases | Worse | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.453 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.427 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.345 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0.12 to 1.78) · 2,583 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 181.61 (147.16 to 216.07) · 200 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.6 · 101 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 130 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.3 · 266 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 619 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.3 · 815 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 1,115 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 7,459 cases | None | Jul 2024 – Jun 2025 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.11 to 0.45) · 12,099 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.17 (0 to 2.44) · 1,411 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.9 (1.73 to 4.06) · 3,175 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.07 (2.95 to 11.2) · 1,400 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.22 (1.54 to 6.91) · 1,481 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.45 (0.06 to 2.83) · 821 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 163 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.751 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.143 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 501 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.2 · 1,438 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 10.8 · 272 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -5 · 698 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 15.4 · 799 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.4 · 1,657 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.6 (5.1 to 8.6) · 477 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.2 (9.1 to 13.9) · 477 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 171 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.4 · 122 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 17.5 · 353 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.6 (10 to 16.1) · 2,546 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 768 cases | No different | Jan 2024 – Dec 2024 |
What patients said (3,104 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 73% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 52% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Medicaid work
$3,390 in 2021
Medicaid paid $3,390 for 72 billed services this clinician did in 2021, up to 21 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 72 | $3,390 |
| 2021 | 72 | 1 | 21 | $3,390 |
Drugs they prescribed that Part D paid
$297,487
Pharmacies billed $297,487 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 13% of their Part D prescriptions (23 of 172) in 2024. A higher opioid share than 9 in 10 peers; the typical hospitalist clinician is at 4%. Long-acting opioids: 48% of their opioid prescriptions.
130 generic and 42 brand-name prescriptions · $297,487 in drug cost · 18 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Acyclovir | 25 | $277 | $11 |
| Morphine Sulfate Er | 11 | $136 | $12 |
| Sulfamethoxazole-Trimethoprim | 12 | $48 | $4 |
Year by year
| 2024 | 172 | 33 | 13% (23) | 24% | $297,487 |
| 2023 | 56 | 15 | 21% (12) | None | $93,352 |
| 2022 | 58 | 18 | None | None | $3,216 |
| 2021 | 37 | None | 0% (0) | None | $2,735 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2022: 1 drug
| Acyclovir | 13 | $421 | $32 |
Money from drug and device companies
$763 in 2025
| 2025 | 19 | 27 | None | $763 |
| 2024 | 15 | 16 | None | $733 |
| 2023 | 11 | 14 | None | $419 |
| 2022 | 2 | 2 | None | $293 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Imfinzi | $107 | 4 payments
|
| Astellas Pharma US | None | $100 | 1 payment
|
| Janssen Biotech | Tecvayli | $70 | 3 payments
|
| Abbvie | Creon | $56 | 2 payments
|
| Novartis Pharmaceuticals | Lutathera | $55 | 2 payments
|
| Merck Sharp & Dohme | Welireg | $53 | 2 payments
|
See all 27 published payments
| Janssen Biotech | Meals · 2025-11-11 | Darzalex | $24 |
| Incyte | Meals · 2025-11-05 | Jakafi | $14 |
| BeOne Medicines USA | Meals · 2025-10-28 | Brukinsa | $17 |
| Merck Sharp & Dohme | Meals · 2025-10-22 | Keytruda | $19 |
| Novartis Pharmaceuticals | Meals · 2025-10-21 | Kisqali | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-16 | Lynparza | $23 |
| Novartis Pharmaceuticals | Meals · 2025-10-14 | Lutathera | $31 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-08 | Imfinzi | $29 |
| Pfizer | Meals · 2025-10-07 | Xtandi | $21 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-09-25 | Ninlaro | $27 |
| Janssen Biotech | Meals · 2025-09-23 | Tecvayli | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-23 | Imfinzi | $24 |
| Eisai | Meals · 2025-09-10 | Lenvima | $17 |
| Abbvie | Meals · 2025-09-09 | Epkinly | $27 |
| Regeneron Healthcare Solutions | Meals · 2025-06-30 | Libtayo | $36 |
| GlaxoSmithKline | Meals · 2025-06-23 | Jemperli | $26 |
| Aveo Pharmaceuticals | Meals · 2025-06-16 | Fotivda | $25 |
| Janssen Biotech | Meals · 2025-06-09 | Tecvayli | $23 |
| Astellas Pharma US | Education · 2025-05-21 | None | $100 |
| Alexion Pharmaceuticals | Meals · 2025-04-21 | Ultomiris | $18 |
| Merck Sharp & Dohme | Meals · 2025-04-07 | Welireg | $33 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-14 | Enhertu | $31 |
| Daiichi Sankyo | Meals · 2025-03-03 | Vanflyta | $27 |
| Abbvie | Meals · 2025-02-04 | Creon | $29 |
| Geron | Meals · 2025-01-27 | Rytelo | $36 |
| Stemline Therapeutics | Meals · 2025-01-14 | Orserdu | $35 |
| Spectrum Pharmaceuticals | Meals · 2025-01-06 | Rolvedon | $23 |
See earlier years (2024, 2023, 2022)
2024: $733
| E.R. Squibb & Sons L.L.C. | Opdivo | $154 | 1 payment
|
| Incyte | Monjuvi | $126 | 1 payment
|
| ADC Therapeutics America | None | $109 | 1 payment
|
| Abbvie | Creon | $45 | 2 payments
|
| Genentech USA | Lunsumio | $35 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $33 | 1 payment
|
| Karyopharm Therapeutics | Xpovio | $31 | 1 payment
|
| Regeneron Healthcare Solutions | Libtayo | $30 | 1 payment
|
| Pfizer | Elrexfio | $30 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Fruzaqla | $27 | 1 payment
|
| GlaxoSmithKline | Ojjaara | $25 | 1 payment
|
| Mirati Therapeutics | Krazati | $23 | 1 payment
|
| Myriad Genetic Laboratories | Precisetumor | $23 | 1 payment
|
| Aveo Pharmaceuticals | Fotivda | $22 | 1 payment
|
| Rigel Pharmaceuticals | Rezlidhia | $21 | 1 payment
|
2023: $419
| AstraZeneca Pharmaceuticals LP | Lynparza | $169 | 4 payments
|
| Takeda Pharmaceuticals U.S.A. | Alunbrig | $30 | 1 payment
|
| Blueprint Medicines | Ayvakit | $30 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $30 | 1 payment
|
| GlaxoSmithKline | Zejula | $27 | 1 payment
|
| Genentech USA | Venclexta | $26 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $23 | 1 payment
|
| Janssen Biotech | Erleada | $22 | 1 payment
|
| ADC Therapeutics America | None | $21 | 1 payment
|
| Incyte | Jakafi | $21 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $19 | 1 payment
|
2022: $293
| Seagen | Adcetris | $150 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $144 | 1 payment
|
Professional record
- NPI
- 1679078257
- Licence
- CA A164599California A164599: Delinquent · expires 2025-08-31
- Trained
- University of Hawaii John A. Burns School of Medicine, 2018
- Group
- The Queens Medical Center · Queens University Medical Group
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Hospitalist (208M00000X); Student in a training program (390200000X)
- Mailing address
- 505 Parnassus Ave, San Francisco, CA, 94143
- NPI first listed
- 2018-03-27
- NPI last updated
- 2021-06-30
- NPI record certified
- 2021-06-30
This is when the NPI record was last certified, not a medical board exam.